清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

托法替尼 甲氨蝶呤 医学 类风湿性关节炎 Janus激酶抑制剂 痹症科 血沉 关节炎 内科学 胃肠病学 外科
作者
Eun Bong Lee,Roy Fleischmann,Stephen Hall,Bethanie E. Wilkinson,John D. Bradley,David C. Gruben,Tamás Koncz,Sriram Krishnaswami,Gene V. Wallenstein,Chuanbo Zang,Samuel H. Zwillich,Ronald van Vollenhoven
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:370 (25): 2377-2386 被引量:787
标识
DOI:10.1056/nejmoa1310476
摘要

BACKGROUND: Methotrexate is the most frequently used first-line antirheumatic drug. We report the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared with methotrexate monotherapy in patients with rheumatoid arthritis who had not previously received methotrexate or therapeutic doses of methotrexate. METHODS: We randomly assigned 958 patients to receive 5 mg or 10 mg of tofacitinib twice daily or methotrexate at a dose that was incrementally increased to 20 mg per week over 8 weeks; 956 patients received a study drug. The coprimary end points at month 6 were the mean change from baseline in the van der Heijde modified total Sharp score (which ranges from 0 to 448, with higher scores indicating greater structural joint damage) and the proportion of patients with an American College of Rheumatology (ACR) 70 response (≥70% reduction in the number of both tender and swollen joints and ≥70% improvement in three of five other criteria: the patient's assessment of pain, level of disability, C-reactive protein level or erythrocyte sedimentation rate, global assessment of disease by the patient, and global assessment of disease by the physician). RESULTS: Mean changes in the modified total Sharp score from baseline to month 6 were significantly smaller in the tofacitinib groups than in the methotrexate group, but changes were modest in all three groups (0.2 points in the 5-mg tofacitinib group and <0.1 point in the 10-mg tofacitinib group, as compared with 0.8 points in the methotrexate group [P<0.001 for both comparisons]). Among the patients receiving tofacitinib, 25.5% in the 5-mg group and 37.7% in the 10-mg group had an ACR 70 response at month 6, as compared with 12.0% of patients in the methotrexate group (P<0.001 for both comparisons). Herpes zoster developed in 31 of 770 patients who received tofacitinib (4.0%) and in 2 of 186 patients who received methotrexate (1.1%). Confirmed cases of cancer (including three cases of lymphoma) developed in 5 patients who received tofacitinib and in 1 patient who received methotrexate. Tofacitinib was associated with increases in creatinine levels and in low-density and high-density lipoprotein cholesterol levels. CONCLUSIONS: In patients who had not previously received methotrexate or therapeutic doses of methotrexate, tofacitinib monotherapy was superior to methotrexate in reducing signs and symptoms of rheumatoid arthritis and inhibiting the progression of structural joint damage. The benefits of tofacitinib need to be considered in the context of the risks of adverse events. (Funded by Pfizer; ORAL Start ClinicalTrials.gov number, NCT01039688.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被6666采纳,获得10
3秒前
懦弱的绿蝶完成签到,获得积分10
5秒前
奋斗的白开水完成签到,获得积分10
6秒前
陵墨完成签到,获得积分10
9秒前
notsoeasy完成签到,获得积分10
11秒前
整齐的开山完成签到,获得积分10
12秒前
516165165完成签到,获得积分10
12秒前
12秒前
小巧的绮完成签到,获得积分10
14秒前
越过山丘完成签到,获得积分10
14秒前
null的应助被369ninja采纳,获得10
15秒前
求助完成签到,获得积分10
16秒前
幸福的盼芙完成签到,获得积分10
16秒前
独特的又菱完成签到,获得积分10
17秒前
ryyy1208完成签到,获得积分10
17秒前
ybcy完成签到,获得积分10
18秒前
wrxaa完成签到,获得积分10
19秒前
21秒前
大力的映天完成签到,获得积分10
22秒前
潘润朗完成签到,获得积分10
22秒前
qimoqi完成签到,获得积分10
23秒前
ln完成签到,获得积分10
23秒前
莫忘初心完成签到,获得积分10
23秒前
24秒前
24秒前
搜集达人的应助被TingtingGZ采纳,获得10
26秒前
友好语风完成签到,获得积分10
28秒前
NiaoJiang完成签到,获得积分10
28秒前
Wtony完成签到 ,获得积分0
28秒前
INC完成签到,获得积分10
30秒前
迷人的危险最值钱完成签到,获得积分10
32秒前
美好的初翠完成签到,获得积分10
33秒前
July完成签到,获得积分10
33秒前
kkdg完成签到,获得积分10
35秒前
邓大瓜完成签到,获得积分10
35秒前
脑洞疼的应助被369ninja采纳,获得10
35秒前
MaidLingYan完成签到,获得积分10
39秒前
39秒前
39秒前
DrPika完成签到,获得积分10
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173194
求助须知:如何正确求助?哪些是违规求助? 9565558
关于积分的说明 21780496
捐赠科研通 7767299
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555697
邀请新用户注册赠送积分活动 2476688